BACKGROUND AND OBJECTIVES: Although well-described for patients who require dialysis, information on transfusion burden related to anemia in the nondialysis patient population with chronic kidney disease (CKD) is lacking. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: A retrospective study was conducted of patients with CKD and chronic anemia from 2002 through 2007 in the Veterans Administration Healthcare System. Included patients had stage 3 CKD or higher and anemia (one or more hemoglobin [Hb] levels <11 g/dl or received anemia therapy [erythropoiesis-stimulating agents [ESAs], iron, or both]). The outcome of interest was transfusion events, which was evaluated in relation to the absolute Hb level and changes in Hb levels overall and according to the type of treatment received (no treatment, iron therapy, ESA therapy, or ESA and iron therapy) concurrent with each Hb measurement. RESULTS: Among 97,636 patients with CKD and anemia, we observed 68,556 transfusion events (61 events per 100 person-years), 86.6% of which occurred in inpatient settings. At all Hb levels, transfusion events were highest during periods of no treatment and increased with declining Hb levels. Between an Hb of 10.0 and 10.9 g/dl, the transfusion rate was 2.0% for those who received an ESA, iron, or both and 22% for those who received no treatment; at an Hb level of 7.0 to 7.9 g/dl, the transfusion rate was 10 to 12% for treated and 58% for untreated patients. Low absolute Hb levels but not Hb changes was most predictive of a transfusion even after adjustment for patient case mix. CONCLUSIONS: Transfusions are still used to treat anemia in patients who have CKD and do not require dialysis, although they occur considerably less frequently in patients who receive other available anemia therapies.
BACKGROUND AND OBJECTIVES: Although well-described for patients who require dialysis, information on transfusion burden related to anemia in the nondialysis patient population with chronic kidney disease (CKD) is lacking. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: A retrospective study was conducted of patients with CKD and chronic anemia from 2002 through 2007 in the Veterans Administration Healthcare System. Included patients had stage 3 CKD or higher and anemia (one or more hemoglobin [Hb] levels <11 g/dl or received anemia therapy [erythropoiesis-stimulating agents [ESAs], iron, or both]). The outcome of interest was transfusion events, which was evaluated in relation to the absolute Hb level and changes in Hb levels overall and according to the type of treatment received (no treatment, iron therapy, ESA therapy, or ESA and iron therapy) concurrent with each Hb measurement. RESULTS: Among 97,636 patients with CKD and anemia, we observed 68,556 transfusion events (61 events per 100 person-years), 86.6% of which occurred in inpatient settings. At all Hb levels, transfusion events were highest during periods of no treatment and increased with declining Hb levels. Between an Hb of 10.0 and 10.9 g/dl, the transfusion rate was 2.0% for those who received an ESA, iron, or both and 22% for those who received no treatment; at an Hb level of 7.0 to 7.9 g/dl, the transfusion rate was 10 to 12% for treated and 58% for untreated patients. Low absolute Hb levels but not Hb changes was most predictive of a transfusion even after adjustment for patient case mix. CONCLUSIONS: Transfusions are still used to treat anemia in patients who have CKD and do not require dialysis, although they occur considerably less frequently in patients who receive other available anemia therapies.
Authors: Francesca Cardarelli; Manuel Pascual; Nina Tolkoff-Rubin; Francis L Delmonico; Waichi Wong; David A Schoenfeld; Hui Zhang; A Benedict Cosimi; Susan L Saidman Journal: Transpl Int Date: 2005-05 Impact factor: 3.782
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Ronald L Pisoni; Brenda W Gillespie; David M Dickinson; Kenneth Chen; Michael H Kutner; Robert A Wolfe Journal: Am J Kidney Dis Date: 2004-11 Impact factor: 8.860
Authors: William McClellan; Stephen L Aronoff; W Kline Bolton; Sally Hood; Daniel L Lorber; K Linda Tang; Thomas F Tse; Brian Wasserman; Marc Leiserowitz Journal: Curr Med Res Opin Date: 2004-09 Impact factor: 2.580
Authors: J P New; T Aung; P G Baker; G Yongsheng; R Pylypczuk; J Houghton; A Rudenski; R P New; J Hegarty; J M Gibson; D J O'Donoghue; I E Buchan Journal: Diabet Med Date: 2008-05 Impact factor: 4.359
Authors: Steven Fishbane; Carol A Pollock; Mohamed El-Shahawy; Elizabeth T Escudero; Anjay Rastogi; Bui Pham Van; Lars Frison; Mark Houser; Maksym Pola; Dustin J Little; Nicolas Guzman; Pablo E Pergola Journal: J Am Soc Nephrol Date: 2022-04 Impact factor: 10.121
Authors: Robert Toto; Jeffrey Petersen; Jeffrey S Berns; Eldrin Foster Lewis; Qui Tran; Matthew R Weir Journal: J Am Soc Nephrol Date: 2020-12-07 Impact factor: 10.121
Authors: Daniel W Coyne; Simon D Roger; Sug Kyun Shin; Sung Gyun Kim; Andres A Cadena; Moustafa A Moustafa; Tak Mao Chan; Anatole Besarab; Willis Chou; Charles Bradley; Meraf Eyassu; Robert Leong; Tyson T Lee; Khalil G Saikali; Lynda Szczech; Kin-Hung P Yu Journal: Kidney Int Rep Date: 2020-12-05
Authors: Jan-Christoph Galle; Kathleen Claes; Istvan Kiss; Christopher G Winearls; Hans Herlitz; Alain Guerin; Salvatore Di Giulio; Michael G Suranyi; Ian Bridges; Janet Addison; Mourad Farouk Journal: Nephrol Dial Transplant Date: 2011-12-02 Impact factor: 5.992
Authors: Mary A M Rogers; M Todd Greene; Jennifer A Davis; David Ratz; Latoya E Kuhn; Sanjay Saint; Vineet Chopra Journal: J Clin Outcomes Manag Date: 2017-09
Authors: Matthew Gitlin; J Andrew Lee; David M Spiegel; Jeffrey L Carson; Xue Song; Brian S Custer; Zhun Cao; Katherine A Cappell; Helen V Varker; Shaowei Wan; Akhtar Ashfaq Journal: BMC Nephrol Date: 2012-11-02 Impact factor: 2.388